CIRC Strikes Strategic Nuclear Technology Pact With Maoming City Government

China Isotope & Radiation Corp. ( (HK:1763) ) has issued an announcement.

China Isotope & Radiation Corporation and its subsidiary Zhonghe Headway have signed a strategic cooperation agreement with the People’s Government of Maoming Municipality in Guangdong Province. The partnership aims to pool resources and policy support to deepen the development of nuclear technology applications in western Guangdong.

Under the agreement, the parties plan to build Maoming into a key base for stable isotope R&D and production and a demonstration zone for nuclear medicine in Southern China. The initiative is intended to enhance the resilience, safety, and security of China’s nuclear technology application industry chain, potentially strengthening CIRC’s regional footprint and role in the country’s nuclear medicine and isotope supply ecosystem.

The most recent analyst rating on (HK:1763) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.

More about China Isotope & Radiation Corp.

China Isotope & Radiation Corporation is a PRC-based company operating in the nuclear technology application sector, with a focus on stable isotope research and production and nuclear medicine applications. Through its subsidiaries, including Zhonghe Headway, the company serves China’s medical and industrial markets by developing and supplying nuclear technology products and solutions.

Average Trading Volume: 192,339

Technical Sentiment Signal: Buy

Current Market Cap: HK$6.72B

For detailed information about 1763 stock, go to TipRanks’ Stock Analysis page.